MOGAD more commonly presents with bilateral optic neuritis and more disc edema at onset, Chen said, with substantial optic ...

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED ...

Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting ...

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.

A multicenter cohort found that adjunctive topical antibiotic documentation was not associated with a statistically ...

Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...

Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular ...

Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including ...

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

Steve Swalgen is national director of lab business, Santinelli International, Hauppauge, NY. Swalgen also is an advisory board member of the Optical Laboratory Association (OLA) and has developed and ...

Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...